Lv11
40 积分 2021-02-20 加入
Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma
3小时前
求助中
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
1个月前
已完结
Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL
1个月前
已完结
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2个月前
已完结
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
2个月前
已完结
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia
1年前
已完结
Blinatumomab Therapy for Low Level Minimal Residual Disease Detected By Next-Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia
1年前
已完结
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
1年前
已完结
Cardiovascular side effects of signaling pathway inhibitors in chronic lymphocytic leukemia therapy
1年前
已关闭
Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?
1年前
已完结
皖公网安备34019202002308
